Hs 683Homo sapiens (Human)Cancer cell line

Also known as: Hs683T, HS 683T, Hs 683.T, HS683, Hs683, Hs-683, HS-683, HS 683

🤖 AI SummaryBased on 13 publications

Hs683

Quick Overview

Human glioma cell line with potential for research in cancer biology and therapeutic development.

Detailed Summary

The Hs683 cell line is a human glioma-derived cell line that has been utilized in various cancer research studies. It is known for its role in investigating the molecular mechanisms of glioblastoma, particularly in relation to the MAP kinase-interacting kinase 1 (MNK1) and its involvement in the TGF-β signaling pathway. Research has shown that Hs683 cells exhibit specific genetic alterations, including mutations in tumor suppressor genes such as TP53, p16/CDKN2A, p14ARF, and PTEN, which are common in gliomas. These characteristics make Hs683 a valuable model for studying the genetic and molecular basis of glioma progression and for testing potential therapeutic strategies. Additionally, Hs683 has been used in studies examining the effects of various drugs on cell proliferation and survival, contributing to the understanding of cancer cell behavior and drug response.

Research Applications

Investigation of MAP kinase-interacting kinase 1 (MNK1) and TGF-β signaling pathwayStudy of genetic alterations in tumor suppressor genes (TP53, p16/CDKN2A, p14ARF, PTEN)Evaluation of drug effects on cell proliferation and survivalAnalysis of glioma progression and molecular mechanisms

Key Characteristics

Human glioma-derived cell lineMutations in key tumor suppressor genesRelevance to glioblastoma researchUtilized in drug response studies

Generated on 6/15/2025

Basic Information

Database ID	CVCL_0844
Species	Homo sapiens (Human)
Tissue Source	Brain, left temporal lobe[UBERON:UBERON_0002808]

Donor Information

Age	76
Age Category	Adult
Sex	Male
Race	caucasian

Disease Information

Disease	Oligodendroglioma
Lineage	CNS/Brain
Subtype	Oligodendroglioma
OncoTree Code	ODG

DepMap Information

Source Type	ATCC
Source ID	ACH-000067_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Arg248Gln (c.743G>A)	Unspecified	Somatic mutation acquired during proliferation	PubMed=20575032

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X,Y

CSF1PO

9,13

D13S317

8,12

D16S539

9,10

D18S51

12,14

D19S433

D21S11

27,33.2

D2S1338

18,20

D3S1358

14,16

D5S818

11,12

D7S820

D8S1179

12,13

FGA

21.2,22

Penta D

13,14

Penta E

13,15

TH01

6,8

TPOX

8,11

vWA

18,20

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOI PubMed PMC

Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.

van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.

Nat. Commun. 10:3574.1-3574.11(2019).

DOI PubMed PMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOI PubMed PMC

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

DOI PubMed

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOI PubMed PMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOI PubMed PMC

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOI PubMed PMC

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Golub T.R., Root D.E., Hahn W.C.

Sci. Data 1:140035-140035(2014).

DOI PubMed PMC

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOI PubMed

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

DOI PubMed

DNA fingerprinting of glioma cell lines and considerations on similarity measurements.

Hamou M.-F., Delorenzi M., Hegi M.E.

Neuro-oncol. 14:701-711(2012).

DOI PubMed PMC

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOI PubMed PMC

MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-beta signaling pathway in human glioblastoma.

Moncayo G., Hemmings B.A.

Cancer Res. 71:2392-2402(2011).

DOI PubMed

Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.

Wolf E., Gabius H.-J.

J. Cancer Res. Clin. Oncol. 127:375-386(2001).

DOI PubMed

Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines.

Van Meir E.G.

Brain Pathol. 9:469-479(1999).

DOI PubMed PMC

Relationship between karyotype of tissue culture lines and tumorigenicity in nude mice.

Gershwin M.E., Lentz D., Owens R.B.

Exp. Cell Biol. 52:361-370(1984).

DOI PubMed

Human brain tumour cell strains with deficient host-cell reactivation of N-methyl-N'-nitro-N-nitrosoguanidine-damaged adenovirus 5.

Day R.S. 3rd, Ziolkowski C.H.J.

Nature 279:797-799(1979).

DOI PubMed

Epithelial cell cultures from normal and cancerous human tissues.";

Owens R.B., Smith H.S., Nelson-Rees W.A., Springer E.L.

J. Natl. Cancer Inst. 56:843-849(1976).

DOI PubMed

Brain tumors.";

Ali-Osman F.

(In book chapter) Human cell culture. Vol. 2. Cancer cell lines part 2; Masters J.R.W., Palsson B.O. (eds.); pp.167-184; Kluwer Academic Publishers; New York; USA (1999).

DOI